05/31/17 11:07 AM EDT

FLASHBACK: Hedgeye Says Buy Exact Sciences | $EXAS

Takeaway: Shares of Exact Sciences are up +100% since our Healthcare team made their buy recommendation.

Shares of Exact Sciences (one of our healthcare team's favorite longs) have surged over 10% today. The stock soared after UnitedHealth Group said it plans to cover the company's colon cancer test starting on July 1. EXAS was targeted by short-seller Citron Research earlier this month -- one of the short-seller's allegations was that UnitedHealth Group wouldn't ever cover the test.

Here's our response to Citron Research earlier this month.

Here's our Sector Head Tom Tobin discussing our long call back in January. The stock is up 100% since then.

FLASHBACK: Hedgeye Says Buy Exact Sciences | $EXAS

4 Tips to Maximize Your Signal Strength Stocks Subscription

Scott Bessent’s ‘Very Tall Order' To Tackle Big U.S. Deficit

REITs Coverage Change: Analyst Brian McGough In The Driver’s Seat

Why to Fade Tesla After Earnings Spike

McDonald’s Food Safety Crisis: Potential 25% Stock Downside

‘Crazy Pain’ In Your Portfolio: A Masterclass on How to Avoid It

WATCH | Current Market Risks + Investing Opportunities

WATCH | Digital Assets Playbook: Crypto Just Went MOON… What Comes Next?

CHART OF THE DAY: Fade the Crowd

CHART OF THE DAY: US Debt Spiraling

WATCH | David Salem Discuses Capital Allocation on Bloomberg

An Open Letter To Fed Chair Powell: 'Mission Accomplished' On Inflation? NO

Cartoon of the Day: On Cloud Nine (Thanks to Three)

CHART OF THE DAY: Our South Korean SHORT vs. Singapore LONG Positions

America Has Been In Recession for Years

Cartoon of the Day: Apocalypse or Pullback? Depends Who You Ask

Sign up for free: Hedgeye's Market Brief